Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

A legfontosabb adatok

Ki végzi
Rutgers, The State University of New Jersey
Hol
New Brunswick (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2022. júl. 29.
Befejezés
2024. aug. 5.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Gemcitabine and Capecitabine
A regiszteradat frissítve
2026. május 7.
Miért állt le
No patients enrolled

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Histologically and/or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma
  • Neoadjuvant chemotherapy (for at least three months) ± chemoradiation followed by R0 surgical resection
  • Eastern Cooperative Oncology Group(ECOG) Performance status of PS 0 - 2
  • At least 18 years of age
  • Adequate bone marrow and organ functions as defined by:; Absolute neutrophil count ≥ 1000 cells/ μL; Hemoglobin ≥ 8 g/ dL; Platelets > 75,000 / μL; Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault; Total bilirubin ≤1.5 ULN; AST/ ALT < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
  • Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately
  • Ability to understand the nature of this study protocol and give written informed consent
  • Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures

Ki nem vehet részt

  • Receipt of any investigational agents at the time of registration
  • Major surgery within the 4 weeks prior to initiation of study treatment
  • Presence of metastatic disease or malignant ascites on diagnostic imaging
  • Presence of any additional active malignancy within the past 3 years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
  • Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure (NYHA classification grade III or IV), unstable angina or active arrhythmia
  • A history of allergy or hypersensitivity to any of the study drugs
  • Severe hepatic impairment
  • Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
  • Known, untreated brain metastases
  • Grade two or greater peripheral neuropathy
  • Pregnancy
  • Participants with known malabsorption

Helyszínek itt: Egyesült Államok

  • Rutgers Cancer Institute of New JerseyNew Brunswick, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Primary Objectives:

A teljes eredeti leírásKevesebb

To determine the disease free survival (DFS) for participants treated with post-operative adjuvant chemotherapy, as compared to neoadjuvant therapy alone.

Secondary Objectives:

To determine the clinical efficacy of the study treatment in terms of median overall survival (OS) and median disease free survival (DFS).

To assess the safety and tolerability of the study treatment regimen as measured by the adverse events rates.

To assess the quality of life in patients receiving the study treatment.

A vizsgálat 2 csoportja

  • Group 1- Gemcitabine and Capecitabine TreatmentA vizsgált kezelés

    Day 1, Day 8, Day 15 • Gemcitabine infused through a vein over 120 minutes Day 1 - Day 21 • Capecitabine tablets will be taken two times a day; once in the morning and once in the evening. The tablets should not be crushed or split and should be taken with a full glass of water (8 ounces/240 milliliters) within 30 minutes after a meal.

    Kezelés: Gemcitabine and Capecitabine

  • Group 2 - ObservationalNincs vizsgálati kezelés, összehasonlításként

    Usual therapy used to treat this type of cancer, chemotherapy plus radiation therapy. If cancer returns during observation, there will be offered standard of care therapy. Follow-up visits will be every three months.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. május 7.